|Bid||0.3050 x N/A|
|Ask||0.3100 x N/A|
|Day's range||0.3050 - 0.3100|
|52-week range||0.2900 - 0.7200|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||15.25|
|Earnings date||12 Feb 2024 - 16 Feb 2024|
|Forward dividend & yield||0.01 (3.28%)|
|Ex-dividend date||04 Sept 2023|
|1y target est||0.70|
Shipment marks the first batch of Psychedelic molecules explicitly for the Authorized Prescriber SchemeVANCOUVER, British Columbia, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is pleased to announce that it has completed its first shipment of MDMA and psilocybin to Cortexa, its 50:50 Australian
It is hard to get excited after looking at Vitura Health's (ASX:VIT) recent performance, when its stock has declined...
Key Insights The projected fair value for Vitura Health is AU$0.25 based on Dividend Discount Model With AU$0.30 share...